Intismeran Plus Keytruda Cuts Recurrence or Death Risk 42% in Phase 3 Trial
MRK sits 81% above its 52-week low of $82.01.
Summary
Merck disclosed the effect sizes behind the Phase 3 INTerpath-001 win it announced in August: adding intismeran autogene to Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone, and by 58% in the subgroup the company highlighted. The combination also reduced the risk of distant metastasis or death by 38%, with that risk halved at six months. No new safety signals emerged and the profile matched earlier studies of the combination. Overall survival data are not yet mature, though Merck says the trend favors the combination. Merck and Moderna will present results from the landmark Phase 3 INTerpath-001 trial for intismeran autogene plus Keytruda at the ESMO 2026 Presidential Symposium. This matters because it hardens the case for an individualized neoantigen therapy layered on top of the company's biggest franchise, at a time when Keytruda's growth is the anchor of Merck's outlook. The OS readout is the remaining piece to prove out.
At the time of this announcement, MRK was trading at $148.37 on NYSE in the Life Sciences sector, with a market capitalization of approximately $366.1B. The 52-week trading range was $82.01 to $156.92. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.